{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:08Z","timestamp":1792704848551,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiretroviral therapy (ART) reduces cancer risk in people with HIV (PWH) but the long-term impact of immediate ART initiation on infection-related and infection-unrelated cancers remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In the Strategic Timing of Antiretroviral Treatment (START) trial, 4684 ART-na\u00efve adult PWH with CD4\u2009+\u2009T-cell count above 500 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      were randomized to immediate or deferred ART initiation arms (i.e., until CD4\u2009+\u2009T-cells below 350 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      ). In May 2015, unblinding revealed a 74% reduction in infection-related cancer risk in the immediate arm. Post-2016, participants in the deferred arm were recommended to start ART, and follow-up continued through 2021. This analysis evaluates cancer incidence (by infection-related and infection-unrelated diagnoses) between the treatment arms by time-period (overall, pre-2016 and post-2016).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 9 years, 120 participants were diagnosed with cancer. The overall hazard ratio (HR) for cancer risk in the immediate versus deferred arms was 0.50 (95% CI: 0.34 to 0.73;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Pre-2016, the HR (immediate vs. deferred) was 0.33 (95% CI: 0.19 to 0.60;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), while post-2016, it was 0.69 (95% CI: 0.42 to 1.13;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.14), and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.062 for the difference. For infection-related cancers in pre-2016 the HR was 0.24 (95% CI: 0.11 to 0.55;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and post-2016, HR was 0.53 (95% CI: 0.23 to 1.18;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.12) and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.18 for the difference. For infection-unrelated cancers, there was no significant difference in HR between immediate and deferred arms in either time period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immediate ART initiation significantly reduces infection-related cancer risk in PWH that persists long-term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>NCT00867048.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16188-8","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:35:14Z","timestamp":1780734914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Ramya","family":"Ramaswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Nordwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Timiryasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Mitsuyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Grabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"23","key":"16188_CR1","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1001\/jama.1985.03350470077024","volume":"253","author":"RL Burkes","year":"1985","unstructured":"Burkes RL, Gal AA, Stewart ML, Gill PS, Abo W, Levine AM. Simultaneous occurrence of Pneumocystis carinii pneumonia, cytomegalovirus infection, Kaposi\u2019s sarcoma, and B-immunoblastic sarcoma in a homosexual man. JAMA. 1985;253(23):3425\u20138.","journal-title":"JAMA"},{"issue":"3","key":"16188_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0002-9343(85)90332-8","volume":"78","author":"CL H","year":"1985","unstructured":"H CL, Masur H, Gelmann EP, Longo DL, Steis RG, Chused T, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med. 1985;78(3):417\u201322.","journal-title":"Am J Med"},{"issue":"3","key":"16188_CR3","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","volume":"11","author":"A Trickey","year":"2024","unstructured":"Trickey A, McGinnis K, Gill MJ, Abgrall S, Berenguer J, Wyen C, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. The Lancet HIV. 2024;11(3):e176\u201385.","journal-title":"The Lancet HIV"},{"issue":"8","key":"16188_CR4","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"A Trickey","year":"2017","unstructured":"Trickey A, May MT, Vehreschild J-J, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV. 2017;4(8):e349\u201356.","journal-title":"The Lancet HIV"},{"issue":"37","key":"16188_CR5","first-page":"861","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","unstructured":"Centers for Disease Control and Prevention (CDC). Update: trends in AIDS incidence -- United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(37):861\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"16188_CR6","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","volume":"72","author":"M-J Horner","year":"2021","unstructured":"Horner M-J, Shiels MS, Pfeiffer RM, Engels EA. Deaths attributable to cancer in the US human immunodeficiency virus population during 2001\u20132015. Clin Infect Dis. 2021;72(9):e224\u201331.","journal-title":"Clin Infect Dis"},{"key":"16188_CR7","doi-asserted-by":"crossref","unstructured":"Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. JNCI: Journal of the National Cancer Institute. 2013;105(16):1221\u20139.","DOI":"10.1093\/jnci\/djt158"},{"issue":"9","key":"16188_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/1055-9965.EPI-21-0008","volume":"30","author":"S Peprah","year":"2021","unstructured":"Peprah S, Engels EA, Horner M-J, Monterosso A, Hall HI, Johnson AS, et al. Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People with HIV, 2000\u20132015. Cancer Epidemiol Biomark Prev. 2021;30(9):1627\u201333.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"11","key":"16188_CR9","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. The Lancet HIV. 2017;4(11):e495\u2013504.","journal-title":"The Lancet HIV"},{"key":"16188_CR10","doi-asserted-by":"crossref","unstructured":"Yuan T, Hu Y, Zhou X, Yang L, Wang H, Li L, et al. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. eClinicalMedicine. 2022;52:1\u201315.","DOI":"10.1016\/j.eclinm.2022.101613"},{"key":"16188_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canep.2017.11.004","volume":"52","author":"NA Hessol","year":"2018","unstructured":"Hessol NA, Ma D, Scheer S, Hsu LC, Schwarcz SK. Changing temporal trends in non-AIDS cancer mortality among people diagnosed with AIDS: San Francisco, California, 1996\u20132013. Cancer Epidemiol. 2018;52:20\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"16188_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7326\/M16-2094","volume":"169","author":"LS Park","year":"2018","unstructured":"Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of viral suppression with lower AIDS-defining and non\u2013AIDS-defining cancer incidence in HIV-infected veterans. Ann Intern Med. 2018;169(2):87\u201396.","journal-title":"Ann Intern Med"},{"issue":"6","key":"16188_CR13","doi-asserted-by":"publisher","first-page":"e0197665","DOI":"10.1371\/journal.pone.0197665","volume":"13","author":"JS Lee","year":"2018","unstructured":"Lee JS, Cole SR, Achenbach CJ, Dittmer DP, Richardson DB, Miller WC, et al. Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS ONE. 2018;13(6):e0197665.","journal-title":"PLoS ONE"},{"key":"16188_CR14","doi-asserted-by":"crossref","unstructured":"Dickey BL, Yanik EL, Thompson Z, Burkholder G, Kitahata MM, Moore RD, et al. The Association of HIV Control and Immunosuppression With Risk of Non\u2013AIDS-Defining Cancer Risk Among Patients on Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2024;95(3):275\u201382.","DOI":"10.1097\/QAI.0000000000003350"},{"issue":"1","key":"16188_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.COH.0000194106.12816.b1","volume":"1","author":"AN Phillips","year":"2006","unstructured":"Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS. 2006;1(1):43\u20139.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"16188_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"The INSIGHT START Study Group","year":"2015","unstructured":"The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807.","journal-title":"N Engl J Med"},{"issue":"3","key":"16188_CR17","first-page":"EVIDoa2200302","volume":"2","author":"The INSIGHT START Study Group","year":"2023","unstructured":"The INSIGHT START Study Group. Long-term benefits from early antiretroviral therapy initiation in HIV infection. NEJM Evid. 2023;2(3):EVIDoa2200302.","journal-title":"NEJM Evid"},{"issue":"12","key":"16188_CR18","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/cid\/ciw621","volume":"63","author":"\u00c1H Borges","year":"2016","unstructured":"Borges \u00c1H, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, et al. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. Clin Infect Dis. 2016;63(12):1668\u201376.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"16188_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/ijc.34727","volume":"154","author":"EA Engels","year":"2024","unstructured":"Engels EA, Shiels MS, Barnabas RV, Bohlius J, Brennan P, Castilho J, et al. State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI. Int J Cancer. 2024;154(4):596\u2013606.","journal-title":"Int J Cancer"},{"issue":"11","key":"16188_CR20","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/cid\/ciaa1046","volume":"72","author":"MJ Silverberg","year":"2021","unstructured":"Silverberg MJ, Leyden W, Hern\u00e1ndez-Ram\u00edrez RU, Qin L, Lin H, Justice AC, et al. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021;72(11):1900\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"16188_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/infdis\/jiy442","volume":"219","author":"\u00c1H Borges","year":"2019","unstructured":"Borges \u00c1H, Neuhaus J, Sharma S, Neaton JD, Henry K, Anagnostou O, et al. The Effect of Interrupted\/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. J Infect Dis. 2019;219(2):254\u201363.","journal-title":"J Infect Dis"},{"key":"16188_CR22","doi-asserted-by":"crossref","unstructured":"Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21(14):1957\u201363.","DOI":"10.1097\/QAD.0b013e3282ed6338"},{"issue":"4","key":"16188_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/cid\/ciy508","volume":"68","author":"L Shepherd","year":"2019","unstructured":"Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d\u2019Arminio Monforte A, et al. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus\u2013infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clin Infect Dis. 2019;68(4):650\u20137.","journal-title":"Clin Infect Dis"},{"key":"16188_CR24","doi-asserted-by":"crossref","unstructured":"Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella d'Aminio M, de Wit S, et al. Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. J Acquir Immune Defic Syndr. 2018;78(5):579\u201388.","DOI":"10.1097\/QAI.0000000000001722"},{"issue":"5","key":"16188_CR25","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","volume":"10","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered t cell subsets, heightened CD8+ t cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.","journal-title":"PLoS Pathog"},{"key":"16188_CR26","doi-asserted-by":"crossref","unstructured":"Sainz T, Serrano-Villar S, D\u00edaz L, Tom\u00e9 MIG, Gurbindo MD, de Jos\u00e9 MI, et al. The CD4\/CD8 ratio as a marker T-cell activation, senescence and activation\/exhaustion in treated HIV-infected children and young adults. AIDS. 2013;27:1513\u20139.","DOI":"10.1097\/QAD.0b013e32835faa72"},{"issue":"1","key":"16188_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jinf.2012.09.013","volume":"66","author":"S Serrano-Villar","year":"2013","unstructured":"Serrano-Villar S, Guti\u00e9rrez C, Vallejo A, Hern\u00e1ndez-Novoa B, D\u00edaz L, Abad Fern\u00e1ndez M, et al. The CD4\/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect. 2013;66(1):57\u201366.","journal-title":"J Infect"},{"issue":"4","key":"16188_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/cid\/ciad671","volume":"78","author":"F Chammartin","year":"2024","unstructured":"Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, et al. Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus. Clin Infect Dis. 2024;78(4):995\u20131004.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"16188_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cid\/ciaa1137","volume":"73","author":"F Caby","year":"2021","unstructured":"Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, et al. CD4\/CD8 ratio and the risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the context of efficiently treated Human Immunodeficiency Virus (HIV) infection: a collaborative analysis of 20 European cohort studies. Clin Infect Dis. 2021;73(1):50\u20139.","journal-title":"Clin Infect Dis"},{"key":"16188_CR30","doi-asserted-by":"crossref","unstructured":"Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, et al. CD4\/CD8 Ratio and Cancer Risk Among Adults With HIV. JNCI: Journal of the National Cancer Institute. 2022;114(6):854\u201362.","DOI":"10.1093\/jnci\/djac053"},{"issue":"4","key":"16188_CR31","doi-asserted-by":"publisher","first-page":"e004564","DOI":"10.1136\/jitc-2022-004564","volume":"10","author":"O Chaudhary","year":"2022","unstructured":"Chaudhary O, Trotta D, Wang K, Wang X, Chu X, Bradley C, et al. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. J Immunother Cancer. 2022;10(4):e004564.","journal-title":"J Immunother Cancer"},{"key":"16188_CR32","doi-asserted-by":"publisher","unstructured":"Lurain KA, Ramaswami R, Krug LT, Whitby D, Ziegelbauer JM, Wang HW, et al. HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus. Clin Microbiol Rev. 2024:e0002223:1\u201348. https:\/\/doi.org\/10.1128\/cmr.00022-23.","DOI":"10.1128\/cmr.00022-23"},{"issue":"4","key":"16188_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1053\/j.seminhematol.2022.11.002","volume":"59","author":"K Lurain","year":"2022","unstructured":"Lurain K, Ramaswami R, Yarchoan R. The role of viruses in HIV-associated lymphomas. Semin Hematol. 2022;59(4):183\u201391.","journal-title":"Semin Hematol"},{"issue":"13","key":"16188_CR34","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462\u201373.","journal-title":"Clin Cancer Res"},{"key":"16188_CR35","doi-asserted-by":"crossref","unstructured":"Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS. 2013;27(11):1735\u201342.","DOI":"10.1097\/QAD.0b013e3283601144"},{"issue":"2_Supplement_1","key":"16188_CR36","doi-asserted-by":"publisher","first-page":"B012-B","DOI":"10.1158\/1538-7445.AGCA22-B012","volume":"83","author":"AE Coghill","year":"2023","unstructured":"Coghill AE, Dickey B, Putney R, Berglund A. Abstract B012: Advanced epigenetic aging in non-AIDS-defining cancer patients living with HIV. Cancer Res. 2023;83(2_Supplement_1):B012-B.","journal-title":"Cancer Res"},{"key":"16188_CR37","doi-asserted-by":"crossref","unstructured":"Gillis N, Dickey BL, Colin-Leitzinger C, Tang Y-H, Putney RM, Mesa TE, et al. Clonal Hematopoiesis in Patients With Human Immunodeficiency Virus and Cancer. The Journal of Infectious Diseases. 2024;230(3):680\u20138.","DOI":"10.1093\/infdis\/jiae212"},{"issue":"1","key":"16188_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cid\/ciy012","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale P, Engels EA, Coghill AE, Kahn AR, Shiels MS. Cancer risk in older persons living with Human Immunodeficiency Virus infection in the United States. Clin Infect Dis. 2018;67(1):50\u20137.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"16188_CR39","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.23.02366","volume":"42","author":"JK McGee-Avila","year":"2024","unstructured":"McGee-Avila JK, Suneja G, Engels EA, Rositch AF, Horner M-J, Luo Q, et al. Cancer Treatment Disparities in People With HIV in the United States, 2001\u20132019. J Clin Oncol. 2024;42(15):1810\u201320.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16188_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.trecan.2016.06.007","volume":"2","author":"JJ Goedert","year":"2016","unstructured":"Goedert JJ, Hosgood HD, Biggar RJ, Strickler HD, Rabkin CS. Screening for cancer in persons living with HIV infection. Trends Cancer. 2016;2(8):416\u201328.","journal-title":"Trends Cancer"},{"issue":"6","key":"16188_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/cncr.31838","volume":"125","author":"KL Corrigan","year":"2019","unstructured":"Corrigan KL, Wall KC, Bartlett JA, Suneja G. Cancer disparities in people with HIV: a systematic review of screening for non-AIDS\u2013defining malignancies. Cancer. 2019;125(6):843\u201353.","journal-title":"Cancer"},{"key":"16188_CR42","doi-asserted-by":"publisher","unstructured":"Horberg M, Thompson M, Agwu A, Colasanti J, Haddad M, Jain M, et al. Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2024:ciae479. https:\/\/doi.org\/10.1093\/cid\/ciae479.","DOI":"10.1093\/cid\/ciae479"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16188-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16188-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:33Z","timestamp":1786460553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16188-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16188"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16188-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"963"}}